*Sponsored
Jeff Ackerman Announces Citius Oncology, Inc. (Nasdaq: CTOR) Just Jumped
To The Top Of This Morning's Early Watchlist
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
See Why We Have All Eyes on (CTOR) Today
Pull Up (CTOR) While It's Still Early…
December 1, 2025
Right Now | Pull Up (Nasdaq: CTOR) And See Why It's Topping Our Radar Today Dear Reader, Earlier this morning, we mentioned that Citius Oncology, Inc. (Nasdaq: CTOR) was already showing strength heading into today's session — but this latest update just turned that early signal into something far more exciting . TradingView's technical analysis dashboard is now firing multiple bullish indicators simultaneously, suggesting a fresh wave of potential momentum may be building in real time. This kind of alignment doesn't show up often, but when there's less than 10M shares listed in its public float, it's hard to look away from (CTOR) right now. When several technical readings flip at once, it's usually a sign that attention is shifting faster than expected. And with (CTOR)'s recent fundamentals already stacking up, this new technical activity adds an important layer to the story developing today. If you missed my earlier email, keep reading to quickly get up to speed on why we're so excited to be highlighting (CTOR) today. A little-known biopharmaceutical company has secured FDA approval for its first commercial therapy — one that enters a space management estimates at more than $400M. An analyst recently set a $6 target on this profile, which suggests a 400% upside potential from its recent $1.20 range. Citius Oncology, Inc. (Nasdaq: CTOR) is one of those rare biopharmaceutical stories where the pieces appear to be aligning at the exact moment they should — and we wanted to get it on your radar this morning, Monday, December 1, 2025. But keep in mind, (CTOR) has less than 10M shares listed as available to the public. When companies have floats this small, the potential exists for big moves if demand begins to shift. And we've already seen what that can look like. Earlier this year, (CTOR) made an approximate 1,000% move, from $0.56 on March 17 to $6.19 on June 27 according to Barchart data. 
Keep reading to see why it just landed on our watchlist. A Rare Cancer Breakthrough Decades in the Making
The turning point came last year, when the FDA granted a biologics license for LYMPHIR, clearing it for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy. This wasn't just any approval. LYMPHIR is a purified reformulation of denileukin diftitox, a cancer immunotherapy first approved in 1999 under the brand name Ontak for the treatment of persistent or recurrent CTCL. The original therapy was voluntarily withdrawn from the market in 2014 due to manufacturing difficulties. Now, after years of refinement, (CTOR) has brought it back — better than ever. LYMPHIR is thought to feature greater purity and bioactivity compared to the original formulation. The therapy works as an IL2-receptor-directed cytotoxin that specifically binds to IL2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. The clinical data speaks for itself. FDA approval for LYMPHIR was driven by strong late-stage results. In the pivotal study, over one-third of patients responded to treatment, and nearly one in ten saw their disease completely clear. Even more striking, 84% had a noticeable reduction in skin tumor burden, with 12.5% experiencing full clearing of skin disease. Targeting a Growing Market with Limited Competition
Cutaneous T-cell lymphoma is a rare but devastating form of non-Hodgkin lymphoma. About 3,000 new cell lymphoma patients are diagnosed in the U.S. each year, and about 16,000 to 20,000 people in the U.S. have mycosis fungoides. Here's what caught our attention about the market dynamics: The North America CTCL therapeutics market is projected to exceed $580M by 2028. Management estimates the initial market for LYMPHIR currently exceeds $400M, is growing, and is underserved by existing therapies. The disease itself affects an aging population, which is expanding. The condition affects males twice as often as females and it affects older people more often than younger people. With diagnostic rates improving by 3% to 6% yearly in the established economies, demand for effective therapies continues to climb. And (CTOR) has already secured critical market access checkpoints. LYMPHIR has been added to the NCCN Clinical Practice Guidelines in Oncology with a Category 2A recommendation which indicates a uniform NCCN consensus that the drug is appropriate as an option for patients with Cutaneous T-cell Lymphoma. Commercial Launch Imminent — Infrastructure Already in Place
What separates Citius Oncology (Nasdaq: CTOR) from many pre-commercial biotechs is the speed and sophistication of its commercialization buildout. The company has locked down distribution partnerships with some of the biggest names in pharmaceutical logistics. (CTOR) signed a U.S. distribution services agreement with McKesson to serve as an authorized distributor of record for LYMPHIR, completing its core U.S. distribution network with all three largest pharmaceutical wholesalers. (CTOR) finalized an exclusive Master Service Agreement with EVERSANA to support the planned U.S. commercialization of LYMPHIR in Q4 2025. EVERSANA will provide an integrated suite of pre- and post-launch services including medical information, pharmacovigilance, revenue cycle management, program management, data and analytics. The company is even deploying cutting-edge technology to maximize its commercial impact. (CTOR) announced the deployment of a proprietary AI platform to enhance its commercial team's performance ahead of the anticipated LYMPHIR launch. The platform leverages advanced data analytics and machine learning to identify potential LYMPHIR candidates and optimize healthcare provider engagement. And here's the timeline: The LYMPHIR launch is on track for Q4 2025.
Recent Capital Raises Signal Confidence
Capital markets have been paying attention. (CTOR) has successfully closed its public offering, raising approximately $9.0M in gross proceeds in recent months to support the commercial launch. On July 17, 2025, (CTOR) completed a public offering generating net proceeds of approximately $7.4M, after deducting placement agent fees and other offering expenses. Expanding Beyond U.S. Borders
While the U.S. launch is the immediate focus, (CTOR) is already building global reach. (CTOR) announced on October 7, 2025 that it is expanding international access to LYMPHIR via country-specific Named Patient Programs (NPPs) in Europe, South America and the Middle East. The company signed an exclusive distribution agreement with Integris Pharma S.A., headquartered in Athens, to cover Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro and North Macedonia. These programs provide early patient access prior to full marketing authorization and create additional revenue opportunities while building brand awareness internationally. The Broader Pipeline: More Than Just LYMPHIR
While LYMPHIR is the star of the show, Citius Oncology (Nasdaq: CTOR) isn't a one-asset story. The company benefits from robust intellectual property protections that span orphan designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors. Leadership Team with Commercial Execution Track Record
Leonard Mazur serves as Executive Chairman of the Board and Chief Executive Officer, with Myron Holubiak as Executive Vice Chairman of the Board and Secretary. The management team has navigated the complex FDA approval process, built a comprehensive commercial infrastructure, and secured major distribution partnerships — all within an aggressive timeline that positions the company for a Q4 2025 launch. 7 Reasons Why (Nasdaq: CTOR) Is Topping Our Watchlist This
Morning—Monday, December 1, 2025.
1. Small Float: With less than 10M shares listed as available to the public, (CTOR)'s small float has the potential for big moves if demand begins to shift. 2. Recent Momentum: Earlier this year, (CTOR) made an approximate 1,000% move, from $0.56 to $6.19, showing its capacity for heightened momentum when conditions line up. 3. Analyst Targett: Maxim Group's $6 target on (CTOR) suggests 400% upside potential from its recent $1.20 range. 4. FDA-Approved Therapy: With LYMPHIR approved and preparing for launch, (CTOR) enters the market with a commercial-ready therapy. 5. High-Growth Segment: The CTCL therapeutics space is projected to exceed $580M by 2028, and (CTOR) is entering a segment management estimates already exceeds $400M. 6. Distribution Network Secured: By partnering with McKesson and major wholesalers, (CTOR) has established national distribution ahead of launch. 7. Global Expansion Underway: Through Named Patient Programs and regional agreements, (CTOR) is extending LYMPHIR's reach internationally even before full authorizations roll out. Pull Up (CTOR) While It's Still Early…
Citius Oncology, Inc. (Nasdaq: CTOR) is stepping into a rare position—one shaped by a small float that could have the potential for big moves if demand begins to shift, a history of powerful momentum earlier this year, and a fresh analyst target that places it firmly on the radar of those watching biopharmas with potential catalysts. Add in an FDA-approved therapy preparing for launch, a rapidly expanding therapeutic segment, distribution agreements with major national partners, and early international access programs already in motion, and (CTOR) is shaping up to be one of the more compelling profiles heading into the new week. We have all eyes on (CTOR) this morning—Monday, December 1, 2025.
Take a look at (CTOR) while it's still early. Also, keep a lookout for my next update, it could be here any moment. Sincerely,
Jeff Ackerman
Managing Editor
Stock News Trends | 
0 Response to "Right Now: Pull Up (Nasdaq: CTOR) And See Why It’s Topping Our Radar Today"
Post a Comment